Helsinn Articles

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16 May 2013

Helsinn grants anamorelin rights to Stendhal for Latin American countries

29 January 2013

Helsinn out-licenses netupitant-palonosetron fixed dose combo in South Korea

25 September 2012

Helsinn moving forward with supportive cancer care products anamorelin and netupitant + palonosetron

26 September 2011

Controversial NSAID nimesulide now banned in China for children below 12

23 May 2011

Helsinn and Taiho Pharma to extend relationship with CINV drug accord

14 April 2011

Helsinn Healthcare enters strategic alliance with IS Pharma, including selling Irish unit

2 February 2011

Zealand Pharma gets milestone from Helsinn on ZP1846 progress

10 December 2010

Helsinn licenses anti-nausea drug Aloxi to Specialised Therapeutics for Australian and New Zealand cancer patients

2 November 2010

Swiss firm Helsinn opens new $16.7 million R&D center in Ireland

7 September 2010

Helsinn's second-generation 5-HT3 RA Aloxi to expand in Asia via deal with Mundipharma

7 July 2010

Helsinn Healthcare and Eisai extend relationship, including US Aloxi marketing

10 June 2010

Showing 1-12 of 12 articles

Go to beginningPrevious
  • 1
NextGo to end